Company intelligence / Profile preview

Mucovax

Worcester, Massachusetts, United Statespitchbook.com ↗

Ownership: Private
Development stage: Other

Overview

Mucovax holds a proprietary mucosal vaccine platform originally developed at Biomere with $14.5 million in funding over 15 years. The company owns three patent families covering methods for tailoring immune responses, novel vaccination approaches for HSV2, and therapeutic vaccines for treating HSV2 infections. No published results from human clinical trials are available as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein (via pichia expression system)
Industry: Biotech

Drug pipeline

2 assets

MucoMilk

1 more asset in the full pipeline.

Request access →

Partnerships

Crozet BioPharma is a key partner working with Mucovax to bring products based on the proprietary technology to market

Beyond the preview

Go deeper on Mucovax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucovax.

Explore the full profile